MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study
- 1 December 2014
- journal article
- research article
- Published by Future Medicine Ltd in Neurodegenerative Disease Management
- Vol. 4 (6), 407-415
- https://doi.org/10.2217/nmt.14.44
Abstract
SUMMARY Aim: using a protocol similar to that of the MOVE 1 study in Germany, the multicenter, observational MOVE 1 EU study examined the burden of multiple sclerosis (MS)-related spasticity in other EU countries (Belgium, Finland, France, Ireland, Norway, Poland and Portugal). Materials & Methods: A 12-month retrospective chart documentation was combined with questionnaires for physicians and patients at the time of enrollment. A total of 281 patients from neurology departments and MS units formed the per protocol population. Results: in most patients, MS spasticity frequently restricted daily activities and caused some/moderate problems in EQ-5D subdomains of mobility, usual activities and pain/discomfort. Overall, 48% of physicians and 34% of patients were at least partly dissatisfied with the effectiveness of available pharmacotherapy options for MS spasticity. Conclusion: Results of the MOVE 1 Germany and MOVE 1 EU studies are aligned and highlight the need to optimize the therapeutic management of patients with MS spasticity across Europe so as to improve their overall well-being and quality of life.Keywords
This publication has 16 references indexed in Scilit:
- Advances in the Management of MS Spasticity: Recent Observational StudiesEuropean Neurology, 2014
- Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of lifeActa Neurologica Scandinavica, 2013
- Incidence and prevalence of multiple sclerosis in Europe: a systematic reviewBMC Neurology, 2013
- Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE studyInternational Journal of Neuroscience, 2013
- Spasticity in multiple sclerosis: results of a patient surveyInternational Journal of Neuroscience, 2013
- Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ studyExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Contribution of impaired mobility and general symptoms to the burden of multiple sclerosisAdvances in Therapy, 2009
- Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trialClinical Therapeutics, 2008
- Improving patient-doctor concordance: an intervention study in general practiceFamily Practice, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983